Mengzhe Zhang

Mengzhe Zhang

Auto-generated profile, based on publicly available information

Mengzhe Zhang

Tianjin Medical University Cancer Institute and Hospital 1 Tianjin

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2026 in Cancer Research
Verified
Journal Article
Closed access
MZMengzhe Zhang
Mengzhe Zhang
ZLZekun Li
Zekun Li
ZXZengtuan Xiao
Zengtuan Xiao
SJShuai Jiang
Shuai Jiang
YDYiying Di
Yiying Di
ZZZhenfa Zhang
Zhenfa Zhang
A substantial proportion of patients with treatment-naïve lung adenocarcinoma (LUAD) exhibit intrinsic resistance to neoadjuvant chemoimmunotherapy, highlighting the need for mechanism-driven therapeutic strategies. In this study, we performed integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics on clinical specimens from the CheckMate 816 trial to define the tumor immune microenvironment (TIME) dynamics associated with therapy resistance. The scRNA-seq data revealed distinct TIME features in nonresponders to neoadjuvant chemoimmunotherapy, characterized by the upregulation of CHCHD3. Mechanistically, CHCHD3 acted as a negative regulator of innate immunity by sequestering cGAS in mitochondria. This interaction between the CHCHD3 domain and the cGAS catalytic core reduced the cytosolic cGAS pool, thereby blunting STING-dependent signaling. Consequently, CHCHD3 knockout restored CXCL5/CXCL1 production, reduced M2-like tumor-associated macrophages, and promoted CD8+ T-cell infiltration. Integrated virtual and functional drug screening identified TN4510 as a small molecule that disrupts the CHCHD3–cGAS interface. TN4510 treatment effectively restored STING signaling and synergized with chemoimmunotherapy to suppress tumor growth in preclinical models. Together, these findings reveal that CHCHD3 drives chemoimmunotherapy resistance by sequestering cGAS to limit STING activation. Targeting CHCHD3 with TN4510 restores antitumor immunity, offering a translatable strategy to overcome treatment resistance in LUAD. Significance: Targeting CHCHD3 activates cGAS-STING signaling to stimulate anti-tumor immunity and sensitize lung cancer to chemoimmunotherapy, highlighting the therapeutic potential of this approach to improve patient outcomes.